First‑line endocrine therapy for hormone receptor positive and HER‑2 negative metastatic breast cancer: A Bayesian network meta‑analysis.

ABSTRACT: Endocrine therapy has become the fundamental treatment option for hormone receptor-positive (HR⁺) and receptor tyrosine-protein kinase erbB-2-negative (HER2^-) metastatic breast cancer (mBC). While treatments incorporating cyclin-dependent kinase (CDK)4 and 6 inhibitors are more prevalent than ever, comparisons among those regimens are scarce. The aim of the present study was to identify the most effective maintenance treatment for patients with HR⁺ and HER2^- mBC. To this end, databases including PubMed, Embase, Cochrane Library, Scopus and Google Scholar were searched from inception to August, 2023. The endpoints comprised overall survival (OS) and progression free survival (PFS). For dichotomous variants, hazard ratios (HRs) and odds ratios (ORs

SUBMITTER: Jiang YC 

PROVIDER: S-EPMC11378012 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature